Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines

doi:10.19803/j.1672-8629.20240621

Abstract

Abstract: Objective To review Current status of updating safety information in labels of Chinese traditional patent medicines. Methods To analyze the guidelines and requirements for the updating of information on adverse reactions, contraindications, precautions and warnings information in the labels of Chinese traditional patent medicines, and to make suggestions based on working experience. Results For some historical reasons, safety information is missing from some Chinese traditional patent medicine labels and should be added to provide guidance to healthcare professionals and patients on the use of medicines. Conclusion Revision of labeling and updating of safety information is one of the risk management measures, after solving the problem of missing safety information, there is still a need for continuous monitoring of adverse reactions, post-marketing research to identify drug risks, and to control the risks by revising labels and other measures.

Key words: Chinese Traditional Medicine, Labels, Safety Information, Adverse Drug Reaction, Contraindications, Precautions

CLC Number:

ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240621

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I2/188

References

[1] NMPA. NMPA Released a Guideline to Implement the Preservation and Innovative Development of Traditional Chinese Medicine(TCM)[EB/OL]. (2020-12-25)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20201225163906151.html.
[2] NMPA. NMPA Released Special Provisions for TCM Registrations[EB/OL]. (2023-02-10)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20230210173401120.html.
[3] State Administration for Market Regulation. Provisions for Drug Registration [EB/OL]. (2020-01-22)[2024-05-30]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_3275cb2a929d4c34ac8c0421b2a9c257.html.
[4] NMPA. NMPA Announcement Application Requirements of Changing Marketed TCM[EB/OL]. (2021-02-24)[2024-05-30].https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210224165613198.html.
[5] NMPA. NMPA Announcement on the Revision of the Package Insert of Xianlinggubao Capsules and Tablets[EB/OL]. (2017-01-09)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20170111165801184.html.
[6] NMPA. NMPA Announcement on the Revision of the Package Insert of 4 Drugs Including Jingwu Capsule[EB/OL]. (2018-01-30)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20180205170801445.html.
[7] NMPA. Announcement on the Conversion of Weitongning Tablets and Three Other Drugs into Prescription Drugs and Revision of the Package Inserts[EB/OL]. (2019-02-25)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20190304104001392.html.
[8] NMPA. Regulations on Package Insert and Labeling of Drug[EB/OL]. (2006-03-15)[2024-05-30]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_b1a64fa4b9314ecabadf3c6662b70c48.html.
[9] NMPA. NMPA Issues a Guideline for TCM and Natural Medicine Descriptions Instructions [R/OL]. (2006-06-22)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20060622010101502.html.
[10] NMPA. NMPA Issues a Guideline for Labels of OTC Drugs[EB/OL]. (2006-10-20)[2024-05-30]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20061020010101266.html.
[11] NMPA. NMPA Issues a Guideline for Updating Safety Information in Labels of TCM[R/OL]. (2022-01-04)[2024-05-30]. https://www.nmpa.gov.cn/yaopin/ypggtg/20220107145808154.html.
[12] NMPA. Good Pharmacovigilance Practices[R/OL]. (2021-05-07)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210513151827179.html.
[13] NMPA. NMPA Announcement on Adopting ICH Level 2 Guidelines [R/OL]. (2018-01-25)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20180125175101686.html.
[14] FU ZH, WANG L, MA PZ.Investigation and Analysis of Pregnancy Contraindication in Package Inserts of 273 Kinds of Chinese Patent Medicine[J]. Chinese Journal of Medicainal Guide(中国医药导刊), 2021, 23(5): 354.
[15] FU HT, CHENG Y, ZHANG QR.Investigation and Analysis of Pregnancy Contraindications and Pediatric Medication Information Labelling in 90 Kinds of Package Inserts of Chinese Patent Medicine90[J]. Herald of medicine(医药导报), 2021, 40(1): 109-114.
[16] NMPA. NMPA Announcement on the Revision of the Package Insert of Qingkailing and Yiqifumai Injections[R/OL]. (2018-06-18)[2024-09-25]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20180703165601192.html.
[17] NMPA. NMPA Announcement on the Revision of the Package Insert of Qingkailing Oral Preparation[R/OL]. (2021-05-06)[2024-09-25]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20210512104440187.html.
[18] ZHU Y, LI Q, ZHU L, et al.Current Situation and Suggestions Concerning the Implementation of MedDRA in Drug Monitoring in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 746-751.